A heart attack triggers an acute inflammatory response at the damaged portion of the heart’s left ventricle. If the inflammation lingers, it can lead heart failure. The inflammation can also claim another victim — the kidneys. New research shows that a bioactive compound called resolvin D-1, injected as a therapeutic dose, is able to limit this collateral damage in the kidneys, as tested in an animal model. This suggests potential application to the clinical setting.